Century Therapeutics (IPSC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Century Therapeutics

NasdaqCM•Healthcare•Biotechnology

$2.11+0.02(0.01%)Market closed

Market Cap

$407.44M

P/B

1.8x

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

How this company scores

WeakMetricSide Score: 31/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (4/25).

Profitability4/25

Growth4/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.8x5y range 0.4x – 666.0x

Currently below its 16-quarter median.

P/B · 1.8x5y range 0.2x – 3.0x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $407.44M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-107.28M
TTM Op. Income: $-116.99M
Q. Op. Income: $-36.53M
TTM Net Income: $-109.79M
Q. Net Income: $-34.55M
EPS: $-0.17
Shares Out.: $205.78M

$0 in TTM revenue declined 100.0% YoY, reaching $0 last quarter. TTM EBITDA of $-107.28M and TTM operating income of $-116.99M show growth is flowing through to the bottom line. However, net income is negative at $109.79M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 100% — a steady trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -3652700000.0%
Net Margin: -3455000000.0%

Op. margin of -3652700000.0% is down 186300000.0% YoY — costs are rising relative to revenue. Net margin at -3455000000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 1.8x

P/S of 0.0x and P/B of 1.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $287.01M
Cash: $49.64M
Long-Term Debt: N/A
Book Value: $232.34M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-19.83M
TTM Free Cash Flow: $-88.09M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-88.09M on $-19.83M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.